Clinical Research Papers:
An integrated analysis of hyponatremia in cancer patients receiving platinum-based or nonplatinum-based chemotherapy in clinical trials (JCOG1405-A)
PDF | HTML | How to cite
Metrics: PDF 1704 views | HTML 2566 views | ?
Yasumasa Ezoe1, Junki Mizusawa2, Hiroshi Katayama2, Kozo Kataoka2 and Manabu Muto1
1Department of Therapeutic Oncology, Kyoto University Graduate School of Medicine, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
2Japan Clinical Oncology Group (JCOG) Data Center/Operations Office, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
Manabu Muto, email: [email protected]
Keywords: hyponatremia; platinum agent; cisplatin; carboplatin; risk factors
Abbreviations: JCOG: Japan Clinical Oncology Group; SIADH: syndrome of inappropriate antidiuretic hormone secretion; NCI-CTC: National Cancer Institute-Common Toxicity Criteria; CI: confidence interval
Received: October 27, 2017 Accepted: December 01, 2017 Published: December 20, 2017
Background: Hyponatremia is a common electrolyte abnormality in cancer patients who receive chemotherapy. Among anticancer agents, platinum-based agents are reported to cause chemotherapy-induced hyponatremia. However, the actual incidence and risk factors remain unknown.
Results: The reports of 29 trials were analyzed. The incidence of grade 3/4 hyponatremia was 11.9% in patients treated with platinum-based chemotherapy and 3.8% in those treated with nonplatinum-based regimens (P < 0.01). Univariable analysis revealed a high incidence of hyponatremia in patients receiving cisplatin, three-drug combination regimen, two-drug combination regimen with amrubicin or irinotecan, or high-dose cisplatin (weekly equivalent cisplatin dose ≥20 mg/m2), and in patients with small-cell lung cancer.
Conclusion: This is the first report of the actual incidence and the potential risk factors of chemotherapy-induced hyponatremia. Careful monitoring of serum sodium level is needed when platinum-based chemotherapy is administered.
Methods: This study included all clinical trials of systemic chemotherapies for solid cancers that were conducted by the Japan Clinical Oncology Group (JCOG) after January 2000 and of which the patient enrolment was completed by January 2014. The latest reports of each trial were used for analysis. The incidence of chemotherapy-induced grade 3/4 hyponatremia and the potential risk factors were investigated with univariable analysis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.